Mendoza, Lorecel M.
HRN: 21-40-90 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/26/2022
CEFUROXIME 750MG (VIAL)
05/26/2022
06/02/2022
IVTT
750mg
Q8
Uti
Waiting Final Action
Indication: Type of Infection: Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes